PIRS News and Press, Pieris Pharmaceuticals Inc. From 05/17/23

2023-05-17 00:55:30 ET Summary Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate. Potential deals on PRS-220 and PRS-343 could bolster the Company's balance sheet. The Company's low...

2023-05-11 13:23:49 ET If you’re like most retail traders, you’re looking for ways to make money in the stock market today. With that, if you’re reading this article, it’s highly likely that you’re on the hunt for the best penny stocks to buy. In this ...

2023-05-10 11:03:07 ET Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Thomas Bures - CFO Stephen Yoder - President and CEO Shane Olwill - Chief Development Officer Conference Call Particip...

2023-05-10 07:11:28 ET Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q1 GAAP EPS of -$0.18 misses by $0.04 . Revenue of $1.94M (-82.3% Y/Y) misses by $4.57M . For further details see: Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, rev...

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDT Enrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohort...

2023-05-09 11:38:25 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$0.09 (-28.6% Y/Y) and the consensus Revenue Estimate is $6.51M (-40.8% Y/Y). Over the...

BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today announced the ...

BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today announced tha...

2023-04-17 14:33:27 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) added ~11% on Monday after announcing the latest data for its investigational bispecific cinrebafusp alfa from a mid-stage trial for patients with HER2-positive gastric cancer at the ongoing annual meeting of the A...

BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the...